Pyrsopoulos, Nikolaos

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update

Yoon, E. D., Babar, A., Choudhary, M. M., Kutner, M., & Pyrsopoulos, N. (2016) · Journal of Clinical and Translational Hepatology

Drug-Induced Hepatotoxicity and ProtectionPoisoning and overdose treatments

Cited by 744

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Vuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 79

Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis c virus: Impact on hepatic fibrosis progression at one year

Kato, T., Gaynor, J. J., Yoshida, H., Montalvano, M., Takahashi, H., Pyrsopoulos, N., Nishida, S., Moon, J., Selvaggi, G., Levi, D., et al. (2007) · Transplantation

Organ Transplantation Techniques and OutcomesHepatitis C virus research

Cited by 77